Skip to main content

Table 2 Cohort BoNTA treatment details

From: A prospective study investigating gross motor function of children with cerebral palsy and GMFCS level II after long-term Botulinum toxin type A use

Study ID number/
Age Group yrs. at assessment
CP type
Predominate tone
Comorbidity BMICurrent
GMFCS/MACS/CFCS
Details of BoNTA treatmentsLower limb surgeryGMFM
Total #LLAge (yrs) first doseAge (yrs) last doseBoNTA dose u/kg
Mean (SD)
BoNTA
u/kg/muscle
Mean (SD)
Upper limb treatmentTotal surgeries/
Age first surgery/type
No. BoNTA doses pre-surgery/post-surgery
Total score (SEM)
95% CI/Centile
#1/6–8Hemiplegia
Dystonia
No 19.1II/I/I4686.7 (0)1.9 (0.3)Yes070.8 (1.6)
67.7–73.9/65th
#2/6–8Hemiplegiaa
Spasticity
Autism 16.1II/III/I7594.6 (1.1)2.6 (0.3)Yes070.0 (1.5)
67–73/60th
#3/6–8Hemiplegia
Spasticity
CHD 16.7II/II/I5368.6 (2.6)4.5 (0.9)Yes083.0 (2.6)
77.9–88/95th
#4/9–10Hemiplegia
Spasticity
CHD 17.0I/II/I8484.7 (0.9)2.2 (0.7)No088 (3.4)
81.3–94.7/50th
#5/9–10Hemiplegiaa
Spasticity
No 15.1I/II/I11385.3 (0.6)5.3 (0.6)No080.9 (2.5)
76.1–85.8/25th
#6/9–10Hemiplegia
Dystonia
No 15.7II/I/I4596.1 (1.2)3.1 (0.6)No076.0 (1.9)
72.2–79.8/50th
#7/11–12Hemiplegia
Spasticity
Autism 29.8II/V/I8494.1 (1.5)2.6 (0.4)Yes051.6 (1.2)
49.1–54.0/< 3rd
#8/11–12Hemiplegia
Spasticity
Epilepsy 20.6II/I/I113103.2 (1.1)2.3 (0.5)Yes072.6 (1.6)
69.4–75.8)/55th
#9/11–12Hemiplegiaa
Spasticity
No 18.2I/II/I182104.4 (2.0)4.4 (2.0)Yes081.9 (2.3)
77.3–86.5/25th
#10/11–12Hemiplegia
Dystonia
Epilepsy, ID 16.0I/II/I95114.8 (1.0)2.4 (0.5)No089.7 (4.1)
81.6–97.8/55th
#11/13–15Hemiplegiaa
Spasticity
Autism, ID 20.9II/IV/IV213156.6 (2.5)4.0 (1.8)Yes1/11 yrs. /Gait
Pre 15/Post 6
64.0 (1.4)
61.2–66.7/20th
#12/16 and overHemiplegia
Dystonia
No 18I/I/I1310152.1 (1.0)2.1 (1.0)Yes096.0 (8.2)
79.0–100/85th
#13/16 and overHemiplegia
Spasticity
No 19.1II/I/I191167.3 (3.5)3.2 (1.4)Yes1/9 yrs./Gait
Pre 14/Post 5
75.3 (1.9)
71.7–79.0/ 65th
#14/6–8Diplegiaa
Spasticity
No 16.6II/I/I12374.6 (1.1)2.6 (0.3)Yes074.7 (1.9)
70.9–78.6/85th
#15/6–8Diplegia
Spasticity
No 15.2II/I/I111816 (4.2)4.3 (0.6)No078.3 (2.1)
74.1–82.4/90th
#16/9–10Diplegia
Spasticity
LD 23II/I/I134109.3 (2.1)3.2 (0.7)No068.9 (1.5)
66.0–71.7/45th
#17/9–10Diplegia
Spasticity
No 19.2I/I/II0NANANANANo085.2 (2.8)
79.7–90.8/35th
#18/9–10Diplegia
Spasticity
No 13.4II/I/I112109.3 (3.2)4.1 (0.8)No072.6 (1.6))
69.4–79.8/60th
#19/9–10Diplegia
Spasticity
Autism 18.7II/III/I2121015.2 (2.2)3.4 (0.7)No067.4 (1.5)
64.5–70.3/35th
#20/9–10Diplegiaa
Spasticity
No 20.4II/I/I151711.6 (2.1)2.8 (0.6)Yes1/9 yrs./Gait
Pre 15
Post 0
68.9 (1.5)
66.0–71.7/40th
#21/11–12Diplegia
Spasticity
ID, ILD 15II/III/III110107.7 (NA)3.9 (NA)No072.6 (1.6)
69.4–75.8/55th
#22/11–12Diplegia
Spasticity
ID 18.1II/I/II781110.0 (1.2)1.8 (0.2)No078.3 (2.2)
73.9–82.7/75th
#23/11–12Diplegiaa
Spasticity
PNI, LD 21II/II/I182117.8 (4.9)3.3 (1.0)Yes1/7 yrs./Gait
Pre 11
Post 7
61.5 (1.3)
59.0–64.0/10th
#24/11–12Diplegia a
Spasticity
Epilepsy 24.4II/II/II1721013.3 (3.2)3.5 (1.4)No070.0 (1.5)
67.0–73.0/40th
#25/11–12Diplegia a
Spasticity
CHD 23II/I/I146125.6 (2.3)1.7 (0.6)No076.0 (2.1)
72.0–80.0/65th
#26/11–12Diplegia a
Spasticity
No 28.6II/I/I2791.4 (0.3)1.4 (0.3)No074.2 (1.8)
70.7–76.7/60th
#27/13–15Diplegia
Dystonia
No 20.2II/III/II272169.0 (2.1)2.8 (1.2)No086.5 (3.10
80.5–92.5/90th
#28/11–12DiplegiaNo 23.2II/I/I67105.6 (2.3)1.7 (0.6)No083.0 (2.5)
78.1–87.8/85th
  1. MACS Manual Ability Classification System, CFCS Communication Function Classification System, CHD congenital heart disease, ID intellectual disability, LD learning difficulties, ILD interstitial lung disease, PNI peripheral nerve injury, NA not applicable
  2. aPain reported present on brief pain inventory. Age at assessment listed as range to maintain deidentified status